Enanta FY26 Q3 net loss widens to $19.5 million; revenue falls to $14.4 million

Reuters2026/08/10 20:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Enanta posted fiscal Q3 revenue of USD 14.4 million, down 21.6% year over year, on lower AbbVie MAVYRET/MAVIRET net sales.
Net loss widened to USD 19.5 million, or USD 0.67 per diluted share.
R&D expense fell to USD 22.1 million from USD 27.2 million, while interest expense more than doubled to USD 4.1 million.
Cash, cash equivalents and marketable securities totaled USD 211.5 million; Enanta expects funding into fiscal 2029 including retained royalties.
Enanta began dosing in the LOTUS pediatric Phase 2b zelicapavir RSV trial, targets RESOLVE initiation in Q4, and expects Phase 1 EDP-978 topline data in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260810427925) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Enanta FY26 Q3 net loss widens to $19.5 million; revenue falls to $14.4 million

You may also like

Crypto prices